Adami S, Marcocci C and Gatti D. Epidemiology of primary hyperparathyroidism in Europe. J Bone Miner Res 2002;17 Suppl. 2:N18–23.
2.
Melton LJ III. Epidemiology of primary hyperparathyroidism. J Bone Miner Res 1991;6 Suppl. 2:S25–30; discussion S31–2.
3.
KhanAABilezikianJPPottsJTJr. (Guest Editors for the Third International Workshop on Asymptomatic Primary Hyperparathyroidism). The diagnosis and management of asymptomatic primary hyperparathyroidism revisited. J Clin Endocrinol Metab2009; 94: 333–334.
4.
ShenWDurenMMoritaE. Reoperation for persistent or recurrent primary hyperparathyroidism. Arch Surg1996; 131: 861–867. discussion 867–869).
5.
HinnieJ. Familial benign hypocalciuric hypercalcaemia. Scott Med J2011; 56: 36–38.
6.
GunnIRWallaceJR. Urine calcium and serum ionized calcium, total calcium and parathyroid hormone concentrations in the diagnosis of primary hyperparathyroidism and familial benign hypercalcaemia. Ann Clin Biochem1992; 29(Pt 1): 52–58.
7.
HinnieJBellEMcKillopE. The prevalence of familial hypocalciuric hypercalcemia. Calcif Tissue Int2001; 68: 216–218.
8.
ShenFHSherrardDJ. Lithium-induced hyperparathyroidism: an alteration of the “set-point”. Ann Intern Med1982; 96: 63–65.
9.
BilezikianJPKhanAAPottsJTJr. (Guest Editors for the Third International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism). Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab2009; 94: 335–339.
10.
SkeltonASmithCMcLarenL. Audit of cost-saving following introduction of investigation protocol for primary hyperparathyroidism. Endocrine Abstr2013; 31: 23–23.
11.
CheungKWangTSFarrokhyarF. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol2012; 19: 577–583.
12.
VestergaardPMollerupCLFrokjaerVG. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ2000; 321: 598–602.
13.
VestergaardPMosekildeL. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ2003; 327: 530–534.
14.
RossiniMGattiDIsaiaG. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J Bone Miner Res2001; 16: 113–119.
15.
ChowCCChanWBLiJK. Oral alendronate increases bone mineral density in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab2003; 88: 581–587.
16.
KhanAABilezikianJPKungAW. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab2004; 89: 3319–3325.
17.
RubinMRLeeKHMcMahonDJ. Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab2003; 88: 1174–1178.
18.
GreyABStapletonJPEvansMC. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism. A randomized, controlled trial. Ann Intern Med1996; 125: 360–368.
19.
PeacockMBilezikianJPKlassenPS. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab2005; 90: 135–141.
